Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2024 Results Conference Call August 1, 2024 4:30 PM ET
Company Participants
Jon Patton - Director of Investor Relations and Communication
Wayne Pisano - Chair of Oncolytics' Board of Directors, and Interim CEO
Tom Heineman - Chief Medical Officer
Christophe Degois - Vice President Business Development
Kirk Look - Chief Financial Officer
Conference Call Participants
John Newman - Canaccord
Soumit Roy - Jones Research
Michael Okunewitch - Maxim Group
Rahul Sarugaser - Raymond James
Operator
Good afternoon, and welcome to Oncolytics Biotech Second Quarter 2024 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communication. Please go ahead.
Jon Patton
Thank you, operator. Earlier today on Oncolytics issued a press release providing recent operational highlights and financial results for the second quarter of 2024. A replay of today's call will be available on the Events section of the Oncolytics website. After remarks from company management will open the call for Q&A.
As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's mission, strategy and milestones, the company's belief as of the potential and mechanism of action of pelareorep as a cancer therapeutic.
Our belief that we are positioned to execute on our key priorities and reach multiple milestones throughout the second half of the year and into 2025. Our potential registrational opportunities for pelareorep anticipated timing of the release of additional data, our cash runway, and other statements related to anticipated developments in the company's business.
These statements are based on management's current expectations and beliefs and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or expectations implied by these forward-looking statements.
In any forward-looking statements, which are Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis. But there can be no assurance that the statement or expectation or belief will be achieved.